Prompt Effect of Progesterone on the Adrenergic Response of Smooth Muscles

Total Page:16

File Type:pdf, Size:1020Kb

Prompt Effect of Progesterone on the Adrenergic Response of Smooth Muscles Prompt Effect of Progesterone on the Adrenergic Response of Smooth Muscles Shigeru MORISHITA Departmentof Pharmacology,Kawasaki Medical School, Kurashiki,Okayama 701 -01, Japan AcceptedJuly 7, 1986 Abstract-1) The contractile effects of epinephrine on the uterus and ductus deferens of the rabbit and the ductus deferens of the monkey were inhibited by the preincubation with progesterone (6.4X10-5 M) for 1 or 3 min in Locke-Ringer solution. Epinephrine relaxed the guinea pig uterus and taenia caecum. The relaxant effects were enhanced by preincubation with progesterone. Their effects were in a dose-dependent manner. 2) There was no apparent change in the number and affinity of alpha-adrenergic receptors in the uterus of rabbits and the ductus deferens of guinea pigs during the incubation with progesterone. Proges terone has no direct effect on alpha-adrenergic receptors. 3) All smooth muscles yielded reproducible contractile reactions to Ca2+ when maintained in depolarizing Tyrode's solution containing K+ (40 mmol/I). Their concentration-response curves were inhibited by preincubation with progesterone (6.4X10-5 M), and they were shifted to the right in a concentration-dependent manner. Established Ca2+ induced contractions were rapidly relaxed by the addition of progesterone (6.4x10-5 M). 4) It suggests that progesterone directly affects the plasma membrane and inhibits the voltage-dependent Ca 21 channel and then inhibits smooth muscle contraction. The hypothesis of a universal mechanism and monkey in relation to the adrenergic of steroid hormone action has been proposed mechanism and the Ca2+ channel. by Thompson and Lippman (1). Although steroids have a classical receptor-mediated Materials and Methods pathway of hormonal action, it is not sufficient Materials: The following drugs were used: to account for all the known effects of steroids. 4-Pregnene-3,20-dione (progesterone), Sig For example, Baulieu and co-workers (2) ma Chemical Co.; epinephrine, Daiichi have demonstrated that progesterone and Chemical Co.; phentolamine mesylate (phen other steroid molecules can promote the tolamine), Ciba Gaigy; dl-propranolol hydro maturation of Xenopus laevis oocytes, chloride (propranolol), Wako Pure Chemical although these cells do not contain steroid Ind.; 3H-dihydroergocryptine and ACSII receptors. Kaya and Saito (3) have recently scintillation mixture, Amersham; All other demonstrated that steroids have a direct, chemicals were purchased from Wako Pure non-genomic effect on the erythrocyte mem Chemical Ind. Progesterone (1 mg) dissolved brane. Therefore, it seems that, in addition to in propylene glycol (0.1 ml) was used in the the receptor-mediated mechanism, steroids Magnus method. Progesterone dissolved in may also operate through other mechanisms 2% ethanol was used in the receptor assay. and, in particular, through an effect on the Deionized distilled water was used in making plasma membrane. In the present paper, I up other solutions. Propylene glycol up to examined the direct, non-genomic effects of 0.1-0.3 ml had no effect on the excitability progesterone on the plasma membrane with of smooth muscles. The 2% ethanol used as a the smooth muscle of the guinea pig, rabbit vehicle had no effect in the receptor assay. Methods: The uterus, ductus deferens and used immediately. taenia caecum (2 3 cm) were dissected from Receptor assay: The assay was done Hartley guinea pig, New Zealand White according to the method of Williams and co rabbit, Flemish giant rabbit and Japanese workers (4). stumptailed macaque Macaca fuscatx. Radioligand: 3H-Dihydroergocryptine was Organs were cleaned of surrounding chosen as the a-adrenergic radioligand for connective tissue, vessels and fat tissue and this study. The reason for using 3H-di set up in a 50 ml Magnus organ bath con hydroergocryptine to identify a-adrenergic taining modified Locke-Ringer solution or receptors was the high potency of dihydro K+-depolarizing Tyrode's solution maintained ergocryptine as an a-adrenergic antagonist. at 37'C and gassed with air. The com Its apparent affinity for a-adrenergic receptors position of the modified Locke-Ringer as determined from pharmacological studies solution (Locke-Ringer solution) was NaCI, is greater than that of any other ergot 154; KCI, 15.6; CaC12, 2.2; M9 C12, 0.98; alkaloid (4). NaHCO3, 11.9; NaH2PO4, 0.4; glucose, 5.5 Membrane preparation: Uterus was ob mM; pH 7.1. K+-depolarizing Tyrode's tained from rabbit, and ductus deferens was solution (K+-Tyrode's solution) was NaCI, obtained from guinea pig. The tissues were 97; KCI, 40; NaHCO3, 11.9; NaH2PO4, 0.4; removed and cleaned of surrounding connec glucose, 5.5 mM; pH 7.1. Contractile and tive tissues in ice cold buffer (0.25 M relaxant responses were measured under sucrose, 1 MM MgC12, 5 mM Tris-HCI, pH isotonic conditions (1 g) using a Nihon 7.4). The tissues were homogenized in 4-5 Kohden isotonic transducer connected to an volumes of the same buffer using a Polytron EGB36069 recorder. When maintained in PT-10 homogenizer at setting 6 for four 10-s Locke-Ringer solution, cumulative concen periods at 0°C. After filtration through a tration-response curves were obtained to single layer of gauze, the homogenate was epinephrine (0.1-100 ,ug/50 ml) by in centrifuged at 400xg for 10 min at 4'C, and creasing the concentration in logarithmic the pellet was discarded. The supernatant increments. To observe the effect of pro was centrifuged at 28000xg for 10 min at gesterone on the Ca2+ channel, K+-Tyrode's 4°C. The resulting pellet was suspended in solution was used. When maintained in K+ the incubation buffer (10 mM MgC12, 50 mM Tyrode's solution, cumulative concentration Tris-HCI, pH 7.5) for use in the binding response curves were obtained to CaC12 assay. (0.03-30 mM) by increasing the Ca2+ con Binding assay: 3H-Dihydroergocryptin centration in logarithmic increments. The (3H-DHE), 0.015 ml (specific activity 15.1 100% response was taken as the maximum Ci/mmol) and the membrane preparation, response (contraction or relaxant) at the 0.1 ml (3 mg protein/ml) were incubated higher epinephrine concentration, and each together for 15 min at 25°C with shaking in response was taken at 1 or 3 min after the a total volume 0.15 ml. Incubations were addition of epinephrine to the bath. Pro terminated by diluting the 0.15 ml incubation gesterone 1 mg/50 ml (6.4x10-5 M) was mixtures with 2.5 ml of incubation buffer added to the bath at 1 min before the (25°C) followed by a rapid filtration through application of catecholamine or CaC12, and a TOYO GC50 glass fiber filter. Filters were concentration-response curves of catechol rapidly washed with 20 ml of incubation amine or CaC12 were measured. The time buffer (25°C). After drying, the filters were required for relaxation of the Ca2+-contracted removed to vials. Five ml of ACS II muscle after the addition of progesterone was (Amersham) scintillation mixture were added compared with the control in which the to each vial, and tritium was assayed by relaxant time was measured after the wash measuring the radioactivity of each sample out. The bath fluid was exchanged each time for 10 min in a liquid scintillation spec for fresh solution, and the organs were then trometer (LSC-900). Counting efficiencies returned passively to their resting tension. were 40%. Nonspecific binding is defined as Epinephrine was dissolved each time and binding under 0.01 mM phentolamine. Fig. 1. Scatchard analysis of 3H-DHE binding in rabbit uterus. Lines were determined by linear regression analysis (r=0.82). Specific binding is defined as the total radioactivity bound minus the nonspecific binding. Membrane preparations were Fig. 2. Effects of progesterone on cumulative con assayed with progesterone (1.31 x10-5 M) centration response curves with epinephrine on in 2% ethanol, and then the binding sites and smooth muscles in Locke-Ringer solution. Control affinity (K,) compared with the control. (J) and progesterone (6.4X10-5 M) added before Progesterone of more than 1.31 x10-5 M the application of epinephrine (A). Progesterone could not be dissolved in 2% ethanol. The displaced the curves with epinephrine in rabbit protein content of the final suspension was uterus, rabbit ductus deferens and monkey ductus determined by the method of Lowry et al. (5). deferens to the right. In contrast, the curves with Student's t-test was used for comparison of epinephrine in guinea pig uterus, guinea pig taenia the mean values. The data from each experi caecum and guinea pig ductus deferens were ment were analyzed by a Scatchard plot. shifted to the left. (Fig. 1). Results Progesterone (6.4x10-5 M) added to the Contractile effect of epinephrine in Locke bath 1 or 3 min before the application of Ringer solution: The uterus (rabbit) and the epinephrine inhibited the contract le effect of ductus deferens (rabbit, monkey and guinea epinephrine on the rabbit uterus and the pig) were contracted by epinephrine in ductus deferens of rabbit and monkey. The Locke-Ringer solution. The uterus and taenia dose-response curves were shifted to the caecum from guinea pig were relaxed. right (Fig. 2 a, b, c). However, progesterone Those concentration-response curves were enhanced the relaxant effect of epinephrine reproducible and dose-dependent. (Fig. 2) on the uterus and taenia caecum of guinea These responses did not change under 0.01 pig. In these cases, the dose-response curves mM propranolol, but were greatly reduced by were shifted to the left (Fig. 2 d, e). Proges 0.01 mM phentolamine. terone enhanced the contractile effect of The effects of progesterone on the con epinephrine on the ductus deferens of guinea tractile or relaxant effects of epinephrine: pig.
Recommended publications
  • A Phase I Trial of Tamoxifen with Ribociclib (LEE011) in Adult Patients with Advanced ER+ (HER2 Negative) Breast Cancer
    The TEEL Study: A Phase I Trial of Tamoxifen with Ribociclib (LEE011) in Adult Patients with Advanced ER+ (HER2 Negative) Breast Cancer NCT02586675 Version 12.0 September 14, 2016 TEEL Protocol- Tamoxifen +Ribociclib Page 1 TITLE PAGE The TEEL Study: A Phase I trial of Tamoxifen with Ribociclib (LEE011) in adult patients with advanced ER+ (HER2 negative) breast cancer. Protocol: MCC 18332 Chesapeake IRB Pro00015228 Principal Investigator: Co-Investigators: Statistician: Experimental Therapeutics Program H. Lee Moffitt Cancer Center 12902 Magnolia Drive Tampa, FL 33612 & Comprehensive Breast Program Moffitt McKinley Outpatient Center 10920 N. McKinley Dr. Tampa, FL 33612 Study Site Contact: Protocol Version 12 Date: September 14, 2016 TEEL Protocol- Tamoxifen +Ribociclib Page 2 TITLE PAGE .............................................................................................................................................. 1 SYNOPSIS ................................................................................................................................................... 5 Patient Population ................................................................................................................................. 5 Type of Study ......................................................................................................................................... 5 Prior Therapy......................................................................................................................................... 5
    [Show full text]
  • Preventive Report Appendix
    Title Authors Published Journal Volume Issue Pages DOI Final Status Exclusion Reason Nasal sumatriptan is effective in treatment of migraine attacks in children: A Ahonen K.; Hamalainen ML.; Rantala H.; 2004 Neurology 62 6 883-7 10.1212/01.wnl.0000115105.05966.a7 Deemed irrelevant in initial screening Seasonal variation in migraine. Alstadhaug KB.; Salvesen R.; Bekkelund SI. Cephalalgia : an 2005 international journal 25 10 811-6 10.1111/j.1468-2982.2005.01018.x Deemed irrelevant in initial screening Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine. Amery WK. 1983 Headache 23 2 70-4 10.1111/j.1526-4610.1983.hed2302070 Deemed irrelevant in initial screening Monoamine oxidase inhibitors in the control of migraine. Anthony M.; Lance JW. Proceedings of the 1970 Australian 7 45-7 Deemed irrelevant in initial screening Prostaglandins and prostaglandin receptor antagonism in migraine. Antonova M. 2013 Danish medical 60 5 B4635 Deemed irrelevant in initial screening Divalproex extended-release in adolescent migraine prophylaxis: results of a Apostol G.; Cady RK.; Laforet GA.; Robieson randomized, double-blind, placebo-controlled study. WZ.; Olson E.; Abi-Saab WM.; Saltarelli M. 2008 Headache 48 7 1012-25 10.1111/j.1526-4610.2008.01081.x Deemed irrelevant in initial screening Divalproex sodium extended-release for the prophylaxis of migraine headache in Apostol G.; Lewis DW.; Laforet GA.; adolescents: results of a stand-alone, long-term open-label safety study. Robieson WZ.; Fugate JM.; Abi-Saab WM.; 2009 Headache 49 1 45-53 10.1111/j.1526-4610.2008.01279.x Deemed irrelevant in initial screening Safety and tolerability of divalproex sodium extended-release in the prophylaxis of Apostol G.; Pakalnis A.; Laforet GA.; migraine headaches: results of an open-label extension trial in adolescents.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Suspension D'amm Des Médicaments Par Voie Orale Contenant
    INFORMATION TRANSMISE SOUS L’AUTORITE DE L’ANSM Lettre aux professionnels de Santé Septembre 2013 Communication aux professionnels de santé concernant les restrictions d’indications des médicaments par voie orale contenant : dihydroergotamine, dihydroergocristine, dihydroergocryptine-caféine, nicergoline A destination des : neurologues, ophtalmologistes, cardiologues, chirurgiens vasculaires, phlébologues, angéiologues, gériatres, médecins généralistes, pharmaciens (ville + hôpital) , CRPV Madame, Monsieur, Cher Confrère, En accord avec l’Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) et l’Agence européenne du médicament (EMA), nous vous informons que les médicaments contenant de la dihydroergotamine, de la dihydroergocristine, de la dihydroergocryptine-caféine ou de la nicergoline ne devront plus être utilisés dans les indications suivantes : Dihydroergotamine (SEGLOR, TAMIK, IKARAN, DIHYDROERGOTAMINE AMDIPHARM): • Traitement de fond de la migraine. • Traitement de l’hypotension orthostatique. • Amélioration des symptômes en rapport avec l'insuffisance veinolymphatique (jambes lourdes, douleurs, impatience du primo-decubitus). Dihydroergocristine (ISKEDYL): • Traitement à visée symptomatique du déficit pathologique cognitif et neurosensoriel chronique du sujet âgé (à l’exclusion de la maladie d’Alzheimer et des autres démences). • Traitement d’appoint des baisses d’acuité visuelle et troubles présumés du champ visuel d’origine vasculaire. • Rétinopathies aigües d’origine vasculaire Dihydroergocryptine-caféine (VASOBRAL) : • Traitement d'appoint à visée symptomatique du déficit pathologique cognitif et neurosensoriel chronique du sujet âgé (à l'exclusion de la maladie d'Alzheimer et des autres démences). • Traitement d'appoint du syndrome de Raynaud. Nicergoline (SERMION, NICERGOLINE BIOGARAN, NICERGOLINE EG, NICERGOLINE MYLAN, NICERGOLINE TEVA): • Traitement d'appoint à visée symptomatique du déficit pathologique cognitif et neurosensoriel chronique du sujet âgé (à l'exclusion de la maladie d'Alzheimer et des autres démences).
    [Show full text]
  • United States Patent (19) 11 Patent Number: 6,060,499 Plachetka (45) Date of Patent: *May 9, 2000
    US006060499A United States Patent (19) 11 Patent Number: 6,060,499 Plachetka (45) Date of Patent: *May 9, 2000 54). ANTI-MIGRAINE METHODS AND Centonze, “Evaluation of the efficacy of oral Sumatriptan in COMPOSITIONS USING 5-HTAGONSTS the management of migraine attacks. Clinical Results' WITH LONG-ACTING NSAIDS (1995) La Clinica Teraputica, vol. 146(11), 721-728 (Article in the Italian language, Citation to English language 75 Inventor: John R. Plachetka, Chapel Hill, N.C. abstract only at 727). Dechant, “Sumatriptan. A review of its Pharmacodynamic 73 Assignee: Pozen, Inc., Chapel Hill, N.C. Properties, and Therapeutic Efficacy in the Acute Treatment of Migraine and Cluster Headache” (1992) Drugs, vol. 43(5) * Notice: This patent is Subject to a terminal dis 776-798. claimer. Klapper, “Toward a Standard Drug Formulary for the Treat ment of Headache” (1995) Headache, Apr., 1995, 225-227. 21 Appl. No.: 09/151,912 Oral Sumatriptan Group, “Sumatriptan-An Oral Dose-de fining Study” (1991) Eur: Neurol., vol. 31, 300–305. 22 Filed: Sep. 11, 1998 Thomson, “A Study to Compare Oral Sumatriptan with Oral Aspirin plus Oral Metoclopramide in the Acute Treatment of Related U.S. Application Data Migraine” (1992) Eur: Neurol., vol. 32, 177-184. 62 Division of application No. 08/907,826, Aug. 14, 1997, Pat. Todd, "Naproxen A reappraisal of its Pharmacology, and No. 5,872,145. Therapeutic Use in Rheumatic Diseases and pain States' 60 Provisional application No. 60/024,129, Aug. 16, 1996. (1990) Drugs, vol. 40(1), 91-137. Tokola, “Effects of migraine attack and metoclopramide on (51) Int.
    [Show full text]
  • French Guidelines for the Diagnosis and Management of Migraine in Adults and Children
    French Guidelines for the Diagnosis and Management of Migraine in Adults and Children Gilles Gkraud, MD,l Michel Lank-i-Minet, MD,’ Christian Lucas, MD,3 and Dominique Valade, MD,4 on behalf of the French Society for the Study of Migraine Headache (SFEMC) lDepartment of Neurology, Rangueil Hospital, Toulouse, 2Pain Centel; Pasteur Hospital, Nice, 3Depurtment of Neurology, Sulengro Hospital, Lille, and 4Heuduche Emergency Centel; Lur-iboisi&e Hospital, Paris, France ABSTRACT Background: The French Recommendations for Clinical Practice: Diagnosis and Therapy of Migraine are guidelines concerning the overall management of patients with migraine, including diagnostic and therapeutic strategies and assessment of disability Objective: This article summarizes the guidelines as they apply to adults and children, and proposes future direction for steps toward optimal treatment of migraine in patients in France. Methods: The recommendations were categorized into 3 levels of proof (A-C) according to the National Agency for Accreditation and Evaluation in Health (ANAES) methodology and were based on a professional consensus reached among members of the Working Group and the Guidelines Review Group of the ANAES. Results: The International Headache Society diagnostic criteria for migraine should be used in routine clinical practice. Recommended agents for the treatment of migraine in adults include nonsteroidal anti-inflammatory drugs, acetylsalicylic acid (ASA) monotherapy or in combination with metoclopramide, acetaminophen monotherapy, triptans, ergotamine tartrate, and dihydroergotamine mesylate. Patients should use the medication as early as possible after the onset of migraine headache. For migraine prophylaxis in adults, the following can be used: propranolol, metoprolol, oxetorone, or amitriptyline as first-line treatment, and pizotifen, flunarizine, valproate sodium, or topiramate as second-line treatment.
    [Show full text]
  • Dihydroergocryptine/Caffeine
    27 September 2013 EMA/750625/2013 Assessment report Ergot derivatives containing medicinal products International Non-proprietary Name: dihydroergocryptine/caffeine Procedure number: EMEA/H/A-31/1325 Referral under Article 31 of Directive 2001/83/EC Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 3 1.1. Referral of the matter to the CHMP ......................................................................... 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction......................................................................................................... 3 2.2. Clinical efficacy .................................................................................................... 3 2.2.1. Results ............................................................................................................. 4 2.2.2. Discussion ........................................................................................................ 6 2.3. Clinical safety .....................................................................................................
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0132780 A1 Allen Et Al
    US 2004O132780A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0132780 A1 Allen et al. (43) Pub. Date: Jul. 8, 2004 (54) METHOD AND COMPOSITIONS FOR (52) U.S. Cl. .............................................................. 514/334 TREATING MIGRAINES (76) Inventors: Christopher P. Allen, Doylestown, PA (57) ABSTRACT (US); Phyllis W. Stone, Somerset, NJ (US); Sean Harper, Gwynedd Valley, The present invention relates to a method for treating or PA (US) preventing migraines in a mammalian patient in need of Such treatment or prevention comprising administering to Correspondence Address: Said patient a compound of Formula A or a pharmaceutically MERCKAND COINC Salt, hydrate or N-oxide thereof, in an amount that is PO BOX 2000 effective to treat or prevent migraines. RAHWAY, NJ 070650907 (21) Appl. No.: 10/476,753 (A) SOCH (22) PCT Filed: Apr. 30, 2002 (86) PCT No.: PCT/US02/13750 C N (30) Foreign Application Priority Data 4. N May 4, 2001 (US).......................................... 60/288623 2 Publication Classification (51) Int. Cl." ............................................ A61K 31/444 US 2004/O132780 A1 Jul. 8, 2004 METHOD AND COMPOSITIONS FOR TREATING DETAILED DESCRIPTION MIGRAINES 0007. The present invention encompasses a method for BACKGROUND OF THE INVENTION treating or preventing migraines in a mammalian patient in need of Such treatment or prevention comprising adminis 0001 Migraines are recurrent, often familial, symptom tering to Said patient a compound of Formula A: complexes of periodic attacks of vascular headache. The condition is characterized by intermittent attacks of head ache, preceded by an aura in approximately 15% of patients. The headache is often accompanied by associated Symp SOCH3 toms, most commonly nausea, vomiting, photophobia and phonophobia.
    [Show full text]
  • ARCI Uniform Classification Guidelines for Foreign Substances, Or Similar State Regulatory Guidelines, Shall Be Assigned Points As Follows
    DRUG TESTING STANDARDS AND PRACTICES PROGRAM. Uniform Classification Guidelines for Foreign Substances And Recommended Penalties Model Rule. January, 2019 (V.14.0) © ASSOCIATION OF RACING COMMISSIONERS INTERNATIONAL – 2019. Association of Racing Commissioners International 2365 Harrodsburg Road- B450 Lexington, Kentucky, USA www.arci.com Page 1 of 66 Preamble to the Uniform Classification Guidelines of Foreign Substances The Preamble to the Uniform Classification Guidelines was approved by the RCI Drug Testing and Quality Assurance Program Committee (now the Drug Testing Standards and Practices Program Committee) on August 26, 1991. Minor revisions to the Preamble were made by the Drug Classification subcommittee (now the Veterinary Pharmacologists Subcommittee) on September 3, 1991. "The Uniform Classification Guidelines printed on the following pages are intended to assist stewards, hearing officers and racing commissioners in evaluating the seriousness of alleged violations of medication and prohibited substance rules in racing jurisdictions. Practicing equine veterinarians, state veterinarians, and equine pharmacologists are available and should be consulted to explain the pharmacological effects of the drugs listed in each class prior to any decisions with respect to penalities to be imposed. The ranking of drugs is based on their pharmacology, their ability to influence the outcome of a race, whether or not they have legitimate therapeutic uses in the racing horse, or other evidence that they may be used improperly. These classes of drugs are intended only as guidelines and should be employed only to assist persons adjudicating facts and opinions in understanding the seriousness of the alleged offenses. The facts of each case are always different and there may be mitigating circumstances which should always be considered.
    [Show full text]
  • Dihydroergotoxine Mesylate
    Dihydroergotoxine mesylate sc-203921 Material Safety Data Sheet Hazard Alert Code Key: EXTREME HIGH MODERATE LOW Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME Dihydroergotoxine mesylate STATEMENT OF HAZARDOUS NATURE CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200. NFPA FLAMMABILITY1 HEALTH2 HAZARD INSTABILITY0 SUPPLIER Santa Cruz Biotechnology, Inc. 2145 Delaware Avenue Santa Cruz, California 95060 800.457.3801 or 831.457.3800 EMERGENCY: ChemWatch Within the US & Canada: 877-715-9305 Outside the US & Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112 SYNONYMS "C31-H41-N5-O5.C-H4-O3-S: C35-H41-N5-O5.C-H4-O3-S: C32-H43.N5-O5.C-", H4-O3-S, "a mixture in equal proportions of", "dihydroergocornine mesylate, dihydroergocristine mesylate and", "dihydroergocryptine mesylate (alpha-and beta-forms) 1.5:2.5:1", "dihydroergotoxine mesilate", "dihydroergotoxine mesylate", "dihydroergotoxine methanesulphonate", "dihydroerotoxin mesylate", "dihydrogenated ergot alkaloids", "ergoloid mesylate", "hydrogenated ergot alkaloids", "ergotoxine, dihydro-, monomethanesulfonate", CCK-179, Circanol, "CO-Dergocrine mesylate", "Codergocrine Mesylate", Coristin, Dacoren, DCCK, Deapril-ST, DH-Ergotoxin-forte, Dulcion, Ergodilat, Ergoplus, Hydergin, Hydergina, Hydergine, Ischelium, Niloric, Optamine, Perenan, Progeril, Redergam, Segolan, Secatoxin, Redergin, "ergot alkaloid" Section 2 - HAZARDS IDENTIFICATION CHEMWATCH HAZARD RATINGS Min Max Flammability: 1 Toxicity: 2 Body Contact: 2 Min/Nil=0 Low=1 Reactivity: 1 Moderate=2 High=3 Chronic: 3 Extreme=4 CANADIAN WHMIS SYMBOLS 1 of 8 EMERGENCY OVERVIEW RISK Harmful if swallowed. May cause harm to the unborn child. Possible risk of impaired fertility. Irritating to eyes, respiratory system and skin. POTENTIAL HEALTH EFFECTS ACUTE HEALTH EFFECTS SWALLOWED ! Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual.
    [Show full text]
  • Nomination Background: Hydergine (CASRN: 8067-24-1)
    SUMMARY OF DATA FOR CHEMICAL SELECTION Hydergine®1 8067-24-1 BASIS OF NOMINATION TO THE CSWG Hydergine was identified from a review of substances being promoted as nootropics or "smart drugs" for cognition enhancement in well persons of all ages. Hydergine is also a prescription drug for the treatment of senility and cerebrovascular insufficiency. Hydergine is an ergot alkaloid. Ergot alkaloids have a wide field of therapeutic application, and their biological activities are strongly dependent on their structural conformation. Despite their widespread use, little information on the carcinogenic or mutagenic potential of hydergine or closely related ergot alkaloids was found in the available literature. Information on the genotoxicity of hydergine was mixed and not completely consistent with the results reported for the closely related compound, ergotamine. SELECTION STATUS ACTION BY CSWG: 12/16/99 Studies requested: Standard battery of genotoxicity tests including Ames Salmonella and micronucleus assays Priority: The CSWG does not assign priority to genotoxicity testing Rationale/Remarks: An ergot alkaloid prescription drug recently promoted for use as a “smart drug” for healthy individuals seeking cognition enhancement Mixed results regarding genotoxicity; no information on carcinogenicity Ergot alkaloids have a wide range of effects influenced by small changes in structure which affect receptor site binding 1Hydergine® is a registered trademark of Sandoz Pharmaceuticals; the drug will be referred to as "hydergine" for the purpose of
    [Show full text]
  • Clinical Study ARRAY 818 302 Array Biopharma Inc
    &OLQLFDO6WXG\$55$< 7KH%($&21&5&6WXG\ %LQLPHWLQLE(QFRUDIHQLE$QG&HWX[LPDE&2PEL1HGWR7UHDW %5$)PXWDQW&ROR5HFWDO&DQFHU $0XOWLFHQWHU5DQGRPL]HG2SHQODEHO$UP3KDVH6WXG\RI(QFRUDIHQLE &HWX[LPDE3OXVRU0LQXV%LQLPHWLQLEYV,ULQRWHFDQ&HWX[LPDERU,QIXVLRQDO )OXRURXUDFLO )8 )ROLQLF$FLG )$ ,ULQRWHFDQ )2/),5, &HWX[LPDEZLWKD6DIHW\ /HDGLQRI(QFRUDIHQLE%LQLPHWLQLE&HWX[LPDELQ3DWLHQWVZLWK%5$)9(PXWDQW 0HWDVWDWLF&RORUHFWDO&DQFHU 3URWRFRO9HUVLRQ $SULO 3URWRFRO9HUVLRQ -XO\ 3URWRFRO9HUVLRQ 0D\ 3URWRFRO9HUVLRQ 6HSWHPEHU 3URWRFRO9HUVLRQ $SULO 3URWRFRO9HUVLRQ 6HSWHPEHU 3URWRFRO9HUVLRQ -DQXDU\ 3URWRFRO9HUVLRQ -XO\ (XGUD&71XPEHU ,1'1XPEHU CCI $UUD\%LR3KDUPD,QF :DOQXW6WUHHW %RXOGHU&2 3KRQH )D[ PPD PPD PPD PPD Encorafenib (BRAF V600-mutant inhibitor)/Binimetinib (MEK inhibitor) Array BioPharma Inc. Clinical Study ARRAY-818-302 PRINCIPAL INVESTIGATOR AGREEMENT I have read and understand the contents of the clinical protocol for Clinical Study ARRAY-818-302 dated 11 July 2019 and will adhere to the study requirements as presented, including all statements regarding confidentiality. In addition, I will conduct the study in accordance with the requirements of this protocol and also protect the rights, safety, privacy and well-being of study patients in accordance with the following: • International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use Harmonised Tripartite Guideline for Good Clinical Practice (GCP) E6(R1) • All applicable laws and regulations, including, without limitation, data privacy laws and
    [Show full text]